Recommendations for antibacterial therapy in adults with COVID-19 – An evidence based guideline

  05 October 2020

The Dutch Working Party on Antibiotic Policy constituted a multidisciplinary expert committee to provide evidence-based recommendation for the use of antibacterial therapy in hospitalized adults with a respiratory infection and suspected or proven 2019 Coronavirus disease (COVID-19).

The 2019 Coronavirus (COVID-19) pandemic due to the novel SARS Coronavirus (SARS-CoV-2) has resulted in a sudden, large and prolonged increase in hospitalizations of patients fulfilling the criteria for community-acquired pneumonia (CAP). SARS-CoV-2 can lead to a wide spectrum of disease, ranging from very mild symptoms of upper respiratory tract infection to life-threatening pneumonia. Severe disease is frequently associated with high inflammation marker levels. It is therefore challenging to define if a patient fulfilling criteria for CAP who is positive for SARS-CoV-2 has a bacterial co-infection upon admission. During hospitalization it may be difficult to distinguish between severe COVID-19 and bacterial secondary infections.

Author(s): Elske Sieswerda, Mark G.J. De Boer, Marc M.J. Bonten, Wim G. Boersma, René E. Jonkers, Roel M. Aleva, Bart-Jan Kullberg, Jeroen A. Schouten, Ewoudt M.W. van de Garde, Theo J. Verheij, Menno M. van der Eerden, Jan M. Prins, W. Joost Wiersinga
Effective Surveillance   Healthy Patients  
Back

OUR UNDERWRITERS

Unrestricted financial support kindly provided by

Antimicrobial Resistance Fighter Coalition





Technology Database

Display your AMR Technology, Product and Service

 

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

 

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!